Amalgamated Bank Has $3.11 Million Holdings in Alexion Pharmaceuticals, Inc. (ALXN)

Amalgamated Bank grew its position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 54.4% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 25,568 shares of the biopharmaceutical company’s stock after buying an additional 9,006 shares during the quarter. Amalgamated Bank’s holdings in Alexion Pharmaceuticals were worth $3,111,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently made changes to their positions in ALXN. Russell Investments Group Ltd. raised its position in Alexion Pharmaceuticals by 19.1% during the 1st quarter. Russell Investments Group Ltd. now owns 29,150 shares of the biopharmaceutical company’s stock worth $3,535,000 after buying an additional 4,665 shares during the last quarter. State of Tennessee Treasury Department raised its position in Alexion Pharmaceuticals by 123.9% during the 1st quarter. State of Tennessee Treasury Department now owns 206,344 shares of the biopharmaceutical company’s stock worth $25,017,000 after buying an additional 114,165 shares during the last quarter. State of Wisconsin Investment Board raised its position in Alexion Pharmaceuticals by 24.8% during the 1st quarter. State of Wisconsin Investment Board now owns 138,296 shares of the biopharmaceutical company’s stock worth $16,767,000 after buying an additional 27,477 shares during the last quarter. Mutual of America Capital Management LLC raised its position in Alexion Pharmaceuticals by 3.9% during the 1st quarter. Mutual of America Capital Management LLC now owns 27,995 shares of the biopharmaceutical company’s stock worth $3,394,000 after buying an additional 1,049 shares during the last quarter. Finally, Bienville Capital Management LLC raised its position in Alexion Pharmaceuticals by 20.6% during the 1st quarter. Bienville Capital Management LLC now owns 4,100 shares of the biopharmaceutical company’s stock worth $497,000 after buying an additional 700 shares during the last quarter. Institutional investors own 94.26% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was first reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at https://www.chaffeybreeze.com/2017/09/16/amalgamated-bank-has-3-11-million-holdings-in-alexion-pharmaceuticals-inc-alxn.html.

ALXN has been the subject of a number of analyst reports. Morgan Stanley upgraded shares of Alexion Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $101.08 to $138.00 in a research report on Thursday, May 25th. Cowen and Company restated an “outperform” rating and set a $122.00 price objective on shares of Alexion Pharmaceuticals in a research report on Monday, July 3rd. J P Morgan Chase & Co downgraded shares of Alexion Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research report on Tuesday, May 23rd. SunTrust Banks, Inc. restated a “buy” rating and set a $165.00 price objective on shares of Alexion Pharmaceuticals in a research report on Friday, July 14th. Finally, Leerink Swann restated a “buy” rating on shares of Alexion Pharmaceuticals in a research report on Tuesday, May 23rd. Five investment analysts have rated the stock with a hold rating, twenty have issued a buy rating and three have assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $157.13.

Alexion Pharmaceuticals, Inc. (NASDAQ ALXN) traded up 1.44% during midday trading on Friday, hitting $146.69. 3,713,613 shares of the company’s stock traded hands. The company has a 50 day moving average of $138.83 and a 200-day moving average of $124.75. Alexion Pharmaceuticals, Inc. has a 52 week low of $96.18 and a 52 week high of $149.34. The company has a market capitalization of $32.74 billion, a PE ratio of 63.61 and a beta of 1.40.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 EPS for the quarter, beating the consensus estimate of $1.08 by $0.48. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The firm had revenue of $912.00 million during the quarter, compared to the consensus estimate of $846.15 million. During the same quarter in the prior year, the firm earned $1.13 EPS. Alexion Pharmaceuticals’s revenue for the quarter was up 21.1% on a year-over-year basis. Equities research analysts predict that Alexion Pharmaceuticals, Inc. will post $5.62 earnings per share for the current year.

In other news, Director Ann M. Veneman sold 700 shares of the company’s stock in a transaction on Monday, July 31st. The shares were sold at an average price of $137.74, for a total transaction of $96,418.00. Following the transaction, the director now directly owns 6,315 shares of the company’s stock, valued at approximately $869,828.10. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Ann M. Veneman sold 835 shares of the stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $145.81, for a total transaction of $121,751.35. Following the completion of the sale, the director now directly owns 5,480 shares in the company, valued at $799,038.80. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 17,070 shares of company stock valued at $2,416,869. 4.35% of the stock is owned by insiders.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply